SoriotBeyond's analysis on Soriot2026-08-25 — Investor resistance to a potential AstraZeneca‑Bristol Myers Squibb macrofusion keeps the share price below pre‑talk levelsRecent news mentioning Soriot2026-08-25 — El portazo inversor contra la macrofusión complica la vida a Soriot2026-08-09 — Pascal Soriot, el ‘sir’ que pasó de la ‘banlieue’ a liderar AstraZeneca2026-08-05 — Soriot should explain the curious case of AstraZeneca’s non-dealBrowse the full archive →